Page 158 - CW E-Magazine (8-7-2025)

News from Abroad

PARTNERSHIP

Bayer and China’s Tsinghua University extend

pharma research collaboration

German pharma and chemicals firm, become a model for end-to-end coope-
Bayer and China’s Tsinghua University ration between Chinese universities
(THU) are extending their research and international pharmaceutical com-
collaboration of 16 years by an addi- panies. The signing of the sixth-phase
tional three years, to further accelerate agreement marks a significant mile-
the translation of scientific research stone in our shared mission to accele-
into drug discovery and development rate the translation of basic research
across the pharmaceutical value chain. into impactful therapies,” said Hongwei
Wang, Professor of School of Life
The extended agreement will focus Sciences and Vice-President of
on joint research projects targeting ship has already resulted in over 70 Tsinghua University, and the Bayer
key therapeutic areas, such as oncology, joint research projects and more than Endowed Chair 2018.
cardiovascular and renal diseases, 10 publications in top international ac-
neurology and rare diseases, as well as ademic journals. In 2022, Bayer and With more than 140 years of pre-
immunology. Bayer will continue to THU initiated the ‘Bayer Microfund- sence in China, Bayer continues to
provide funding and support for these ing’ programme to further enhance the expand its innovation footprint. It has
projects, as well as for scientists at translation of early scientific research, established two global research & deve-
THU, in recognition of their research with nine projects receiving funding lopment (R&D) centres and four pro-
excellence in life sciences and pharma- support in the past three years. duction facilities in China. More than
ceutical innovation. Financial details 80% of Bayer’s major multi-centre
of the collaboration were not disclosed. “This collaboration has supported clinical trials are conducted in China,
cutting-edge research targeting major covering both early and late-stage
Established in 2009, this partner- global health challenges and has clinical development.

EXPANDED OFFERINGS
Sartorius Stedim Biotech completes capacity

expansion in France

Sartorius Stedim Biotech, a leading Dr. René Fáber, CEO of Sartorius
supplier of equipment and services to Stedim Biotech.
biopharmaceutical companies, has an-
nounced the completion of a multi-year To meet the growing demand for
capacity expansion project at its head- single-use bioprocessing solutions,
quarters in Aubagne, France. Sartorius Stedim Biotech almost dou-
bled cleanroom space to around 9,000
Launched in 2021, the investments square metres. Automated and digitised
in several new facilities will boost the production lines for 2D and 3D sin-
company’s capabilities in fluid manage- gle-use bags increase productivity and
ment technologies such as single-use “By investing in innovation, auto- reliability. Certified with ISCC Plus,
bags, used for cell culture, storage and mation, and sustainability, we are the site uses renewable raw materials
shipping of fluids in biopharmaceutical strengthening our ability to meet the to produce plastic components, signif-
manufacturing. Sartorius is also deve- evolving needs of our customers while icantly reducing the share of fossil-based
loping a new bioprocessing site in ensuring our competitive positioning materials in products. An automated
South Korea with Samsung E&A. and preparing for future growth,” said logistics facility accelerates raw mate-

158 Chemical Weekly July 8, 2025

Contents Index to Advertisers Index to Products Advertised